市場調査レポート
商品コード
1442598
眼内レンズの世界市場の評価:タイプ別、素材別、用途別、エンドユーザー別、地域別、機会、予測(2017年~2031年)Intraocular Lens Market Assessment, By Type, By Material, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
眼内レンズの世界市場の評価:タイプ別、素材別、用途別、エンドユーザー別、地域別、機会、予測(2017年~2031年) |
出版日: 2024年03月04日
発行: Market Xcel - Markets and Data
ページ情報: 英文 237 Pages
納期: 3~5営業日
|
世界の眼内レンズの市場規模は、予測期間中にCAGR 5.5%で成長し、2023年の50億8,000万米ドルから、2031年には77億9,000万米ドルに成長すると予測されています。
白内障の有病率の増加は、多くの国で経済および医療の大きな課題となっており、各国政府は白内障の撲滅を目指したプログラムを開始しています。白内障は世界の失明原因の第一位であり、罹患者の多くは途上国に居住しています。白内障、さらには老眼や眼瞼下垂症などの角膜疾患の管理は、特に適切な治療へのアクセスが限られている低所得国において、社会経済的な課題となることが予想されています。白内障手術は有効であるにもかかわらず、世界人口の大部分、特に経済的手段や外科医へのアクセスが制限されている途上国では、依然として手の届かない手術です。その結果、相当数の白内障症例が未治療のままであり、白内障という病気の負担の一因となっています。目の健康や新技術の利点や特徴に関する意識は、市場を牽引する主な要因の1つです。
世界保健機関 (WHO) の2023年の報告書によると、世界全体で約22億人が近視または遠視の障害を抱えており、白内障を患っている人は9,400万人と推定されています。政府支援の増加と有利な償還政策により、より多くの患者が白内障手術を受けるようになり、白内障手術装置の採用が増加しています。さらに、白内障手術の滞留を減らすための取り組みや、主要国における眼科医療に対する意識の高まりが、白内障手術機器市場の成長を促進すると予想されています。
白内障手術件数の増加
白内障手術は、世界的にもっとも多く実施されている眼科手術の1つであり、多額の投資と新製品、サービス、技術革新の継続的な流れを引き寄せています。絶え間ない進歩と需要の増加により、白内障手術の将来は有望です。2030年までに白内障手術の年間平均件数は増加し、患者の平均年齢も上昇すると予測されています。白内障手術に対する需要の高まりは、多くの人が白内障に罹患している途上国にも広がっています。2022年1月にScientific Reports誌に発表された研究では、白内障と眼瞼下垂症が高齢者の間で広く見られる眼科的問題であることが明らかになっています。中高年における眼瞼下垂の有病率は10%を超え、白内障は人口の15%に影響を及ぼしています。
単焦点眼内レンズの費用対効果が市場の優位性を牽引
眼内レンズ市場では、安価な単焦点レンズの部門が最大のシェアを示しており、市場の約55%を占めています。この優位性は、製品がより有利に償還されることと、白内障手術に単焦点レンズを利用するための政府の取り組みが増加していることに起因しています。
北米が眼内レンズ市場を独占
北米は世界の眼内レンズ市場で大きなシェアを占めると予想されています。これは、視力関連疾患の有病率の増加、米国とカナダにおける新技術や新製品の採用率の高さ、より良い医療施設に対する需要の急増に起因しています。同地域は白内障手術器具の最大市場であり、米国が大きなシェアを占めると予想されています。2022年5月の眼科経営の最新情報によると、米国には1億2,800万人の老眼患者がおり、この数はミレニアル世代が40歳に達して老眼が進む中で増加を続けています。この動向が今後数年間の眼内レンズ市場を牽引すると予想されています。さらに、加齢性白内障や先天性白内障を含む白内障の有病率の増加も市場成長に寄与すると予測されています。
当レポートでは、世界の眼内レンズの市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。
Global intraocular lens market is projected to witness a CAGR of 5.5% during the forecast period 2024-2031, growing from USD 5.08 billion in 2023 to USD 7.79 billion in 2031. An intraocular lens (IOL) implant is a synthetic lens placed inside the eye to replace the focusing power of the natural lens, typically as part of cataract surgery. It has been approved as safe and effective by the U.S. Food and Drug Administration since 1981. IOLs are a popular option for improving vision without heavy reliance on contact lenses and glasses.
The increasing prevalence of cataracts presents a significant economic and healthcare challenge in many countries, prompting various governments to initiate programs aimed at eliminating cataracts. Cataracts are the leading cause of blindness worldwide, with most of those affected residing in developing countries. The management of cataracts and even other corneal disorders, such as presbyopia and blepharoptosis, is expected to become a socioeconomic challenge, particularly in low-income nations with limited access to appropriate treatment. Despite the effectiveness of cataract surgery, it remains inaccessible to a large portion of the global population, especially in developing countries where financial means and access to surgeons are limited. As a result, a substantial number of cataract cases remain untreated, contributing to the burden of the disease. This shortcoming is a big reason behind the forthcoming surge in market growth of IOLs. Awareness about eye health and the benefits and features of new technology is one of the primary factors driving the market.
According to a 2023 report by the World Health Organization (WHO), approximately 2.2 billion people globally have near or distant vision impairment, and an estimated 94.0 million people suffer from cataracts. The increasing government support and favorable reimbursement policies have encouraged more patients to undergo cataract surgery, leading to a rise in the adoption of cataract surgery devices. Additionally, initiatives to reduce the backlog of cataract surgeries and the growing awareness of eye care in key countries are expected to drive the market growth for cataract surgery devices.
Increasing Volume of Cataract Surgeries
Cataract surgery is one of the most performed ophthalmic procedures globally. The increasing prevalence of cataracts and associated visual impairments has led to a rise in the number of cataract surgeries performed worldwide. Cataract surgery has the highest volume procedure for the ophthalmic industry, attracting significant investments and a continuous flow of new products, services, and innovations. With continuous advancements and growing demand, the future of cataract surgery is promising. It is projected that by 2030, the average annual volume of cataract surgeries will increase, and the mean age of patients will also increase. The rising demand for cataract surgery is also prevalent in developing countries, where many individuals are affected by cataracts. Various initiatives and organizations are dedicated to addressing the global burden of cataract blindness and increasing access to cataract surgery in developing nations. A study published in Scientific Reports in January 2022 revealed that cataracts and blepharoptosis are prevalent ophthalmic issues among older adults. The prevalence of blepharoptosis in middle-aged to older adults exceeds 10%, while cataracts affect 15% of the population.
Cost Effectiveness of Monofocal IOL is Driving its Dominance in the Market
The intraocular lens market is categorized into monofocal and premium segments. The monofocal segment, which is cheaper, held the largest share of the global intraocular lens market, accounting for around 55% of the market. This dominance is attributed to the products being more favorably reimbursed and the rising number of government initiatives for utilizing monofocal lenses for cataract surgeries. The premium segment, on the other hand, is expected to witness growth prospects, with multifocal IOLs being the most adopted product due to their advantages in treating complex vision problems such as presbyopia or astigmatism. According to an article published in 2023 by the National Institutes of Health (NIH), monofocal lenses are among the most implanted products in the intraocular lens market. The popularity of these products among the general population is due to their favorable reimbursement and has contributed to their growth prospects.
Government Initiatives Acting as Catalyst
The increasing prevalence of cataracts presents a significant economic and healthcare challenge in many countries, prompting various governments to initiate programs aimed at eliminating cataracts. The rise in standalone eye clinics in developed and developing regions is also expected to contribute to the segment's growth. The academic and research institutes segment is expected to attain growth prospects due to active government efforts to train ophthalmologists and the increasing number of doctors opting for fellowship programs to learn about the latest medical technologies. According to a news article published by the Hindu in May 2022, the Government of India proposed a special drive to clear the backlog of cataract surgeries. 7.5 million cataract surgeries were performed in FY2022-FY2023, 9 million cataract surgeries were performed in FY2023-FY2024, and the plan for FY2024-FY2025 is 10.5 million surgeries. The number of cataract surgeries will be done under a special campaign to clear the backlog, and all the Indian states will be given guidance to conduct these procedures.
High Demand for Hydrophobic Acrylic IOLs
Hydrophobic acrylic materials are the leading choice in the IOL industry, holding the largest market share. They are versatile and can be used to manufacture various IOL designs, including monofocal, multifocal, and toric lenses, thereby meeting diverse patient needs. Compared to other IOL materials like silicone, they offer a more cost-effective option while maintaining high quality. Additionally, being water-resistant, they do not readily absorb water, which helps prevent the build-up of protein deposits on the IOL's surface and the associated clouding and vision problems over time. Its high refractive index, low water content, and the ability to be inserted through small incisions make it more widely used in cataract surgeries. The PMMA segment is expected to hold the second-largest market position in the forecast period, particularly in Europe and other regions, due to its cost advantage over acrylic products.
In 2023, Alcon developed a new intraocular lens made from a hydrophobic acrylic named "Clareon PanOptix IOL". Clareon IOL is made from a hydrophobic acrylic with increased water content compared to AcrySof. As per a study conducted in Australia to test the efficacy of the product, majority of eyes that had the Clareon IOL implanted showed Grade 0 glistening (problems that can occur when a patient is undergoing cataract surgery), and 92.9% of the patients had either no posterior capsular opacification (PCO) or PCO that was clinically undetectable. Over the course of the three-year study period, the visual outcomes were excellent and stable.
North America Dominates IOL Market
North America is anticipated to hold a significant share of the global intraocular lens market. This can be attributed to the increasing prevalence of vision-related disorders, high adoption of new technologies and products in the United States and Canada, and a surge in demand for better healthcare facilities. The region is expected to be the largest market for cataract surgery devices, with the United States accounting for a significant share of the market. According to the ophthalmology management's update from May 2022, the United States is home to 128 million presbyopes, a number that continues to grow as millennials reach the age of 40 and develop presbyopia. This trend is expected to drive the intraocular lens market in the coming years. Furthermore, the increasing prevalence of cataract issues, including age-related and congenital cataracts, is projected to contribute to market growth. In 2022, approximately 12 million individuals aged 40 and above in the United States were found to have vision impairment, while 1.2 million Canadians were living with vision loss. These factors are anticipated to fuel the development of the intraocular lens market due to the growing prevalence of eye illnesses and the rising demand for intraocular lenses.
Future Market Scenario (2024 - 2031F)
The future market scenario of the global intraocular lens market is marked by continuous advancements and innovations. Technological advancements are expected to redefine the landscape, by improving the efficacy of cataract surgeries and refractive procedures. The integration of smart technologies, such as adjustable focus lenses and auto-adjusting IOLs, may become more prevalent, offering patients personalized vision correction options. Nanotechnology is expected to play an important role in the development of next-generation IOL materials, promoting improved biocompatibility and optical performance. In January 2022, Aston University announced its partnership with Rayner Intraocular Lenses, the first company in the world to manufacture intraocular lenses (IOLs), to develop the next generation of lenses that give patients a full range of vision without the need for glasses.
Key Players Landscape and Outlook
The global intraocular lens market is characterized by a consolidated structure, with a few major players holding a significant proportion of the market. Alcon Inc. accounts for the highest market share with a strong portfolio, including the ACRYSOF product line, and an established geographical presence. The company has also focused on launching new products and strategic initiatives to increase its market share. Johnson & Johnson Vision Care, Inc. is the second leading player, with a strong market presence in key regions and robust distribution networks. The prominent companies in the intraocular lens market are pursuing acquisitions to strengthen their market presence.
Additionally, they are forming partnerships with non-profit organizations to raise awareness about cataracts and other eye conditions. Furthermore, manufacturers are actively engaged in introducing new products to maintain a robust product portfolio. In January 2023, Bausch + Lomb completed the acquisition of AcuFocus, a privately held company known for its small aperture non-toric extended depth of focus (EDOF) intraocular lens (IOL). This acquisition has provided Bausch + Lomb with access to AcuFocus's innovative IOL technology, including the IC-8 Apthera lens, which received FDA approval in July 2022. Johnson & Johnson Vision Care Inc., announced in December 2022 that the TECNIS Synergy Toric II OptiBlue PC-IOL is now available in India for patients with astigmatism.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.